ArticleIndian journal of surgical oncology2025
Utility of HE4 in the Evaluation of Adnexal Masses Among Premenopausal and Postmenopausal Women.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adnexal masses, encompassing a spectrum of benign and malignant conditions, present a diagnostic challenge in clinical practice. The timely and accurate assessment of these masses is paramount for guiding appropriate management strategies and ensuring optimal patient outcomes. In this context, Human Epididymis Protein 4 (HE4) has emerged as a promising biomarker, offering valuable insights into the differential diagnosis and risk stratification of adnexal masses. This study aims to elucidate the evolving role of HE4 in the evaluation of adnexal masses by delineating the diagnostic accuracy, prognostic significance, and clinical implications of HE4 alone or as a part of an algorithm in this context. This study was conducted in the Department of Obstetrics and Gynaecology of JIPMER from September 2017 to January 2019 among women who presented with adnexal mass to gynaecological OPD and were planned for surgery. CA-125 levels were estimated using the direct chemiluminescence method, and HE4 levels were estimated using the ELISA method. RMI and ROMA scores were calculated, and results were compared with the final histopathological report. In the present study, among 160 patients studied, the average age of the study population was 45 years. On histopathology, 59% were reported as benign, whereas 5% and 35% of patients were borderline and malignant, respectively. Among malignant tumours, the majority were epithelial tumours (92%), and among epithelial, the majority were serous (67.6%). In the present study, the sensitivity and specificity of the RMI and ROMA models in the prediction of malignancy was 87.7%, 71.6% and 93.8%, 81.1%, respectively. HE4 independently predicted malignancy in the adnexal masses when used with a cut-off of 70 pmol/L for premenopausal women and 140 pmol/L for post-menopausal women. The ROMA had good diagnostic power in predicting the risk of malignancy in an adnexal mass, with high sensitivity and AUC curve compared to RMI in this study. HE4 independently proved to be useful for predicting ovarian malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.